Glaxo/SB Merger Talks Resume After Management, Manufacturing Changes
Executive Summary
Manufacturing streamlining initiatives undertaken by Glaxo Wellcome and SmithKline Beecham in 1999 may have already begun the cost savings that can be expected from the combination of the British firms.
You may also be interested in...
GlaxoSmithKline Selects European Head Witty To Succeed Garnier As CEO
GlaxoSmithKline's incoming CEO Andrew Witty - the current president of European pharmaceuticals -brings to the post experience with cost-effectiveness that could prove an asset as comparative and cost-effectiveness become increasingly important to the U.S pharmaceutical industry
GlaxoSmithKline Selects European Head Witty To Succeed Garnier As CEO
GlaxoSmithKline's incoming CEO Andrew Witty - the current president of European pharmaceuticals -brings to the post experience with cost-effectiveness that could prove an asset as comparative and cost-effectiveness become increasingly important to the U.S pharmaceutical industry
Glaxo/SB Supply Chain Alignment Will Ease Second Merger Attempt - Garnier
The second attempt at a merger of SmithKline Beecham and Glaxo Wellcome is more likely to succeed because the companies have aligned their manufacturing operations in the two years since the first engagement, CEO-designate Jean-Pierre Garnier, PhD, told the House of Commons Science & Technology Select Committee Feb. 22 in London.